Data collected by the US Centers for Disease Control and Prevention shows an increase in hepatitis A infections with most incidences occurring among homeless persons and drug users. To a small extent, some outbreaks were caused by imported food that was contaminated.
Data that were cross-referenced to monitor all-cause mortality between death records and laboratory diagnoses in the United Kingdom showed that liver disease is reduced once treatment for hepatitis C virus (HCV) infection is implemented, but researchers believe more research is needed to meet the World Health Organization’s global HCV elimination goal.
Researchers found data showing that long-term use of tenofovir disoproxil fumarate for hepatitis B virus was not effective, with a low HBeAg seroconversion rate, and that patients presented with a decrease in renal function and bone mineral density.
An 8- or 12-week regimen of glecaprevir and pibrentasvir is efficacious and safe in patients with HCV infection after liver transplantation.
Treatment with DAAs before liver transplantation is associated with improved outcome and appears to be safe in patients with decompensated hepatitis C-related cirrhosis.
Findings suggest that states should consider revising their HCV treatment policies to include all individuals infected with HCV to achieve significant patient- and population-level benefits.
Report describes progress made to achieve hepatitis B control in the Western Pacific Region and the steps taken to eliminate mother-to-child transmission of hepatitis B virus during 2005 to 2017.
Investigators assessed country, regional, and global incidence of serologically confirmed HIV, anti-hepatitis C virus, and hepatitis B virus prevalence according to gender in people who inject drugs.
A combination treatment of ledipasvir/sofosbuvir with or without ribavirin was an effective and tolerable treatment in patients with chronic hepatitis C and advanced liver disease before and after liver transplantation.
Dataset of 66,640 individuals from 12 countries representative of 6 global regions confirmed that a test with a limit of detection of 1318 IU/mL would identify 97% of viremic HCV infections.
